Jorgensen Nathan D., Chief Financial Officer at Voyager Therapeutics, Inc. (VYGR), sold 7,666 shares on October 03, 2025, at an average price of $4.78, realizing proceeds of about ~$36,641.48. After the transaction, he now holds 123,834 direct shares; no indirect holdings reported. For retail traders, this is a neutral event: sell-to-cover tax withholding under a prearranged 10b5-1 plan.
Decide: Neutral
Neutral. This is a small, prearranged sell-to-cover executed under a 10b5-1 plan (transaction code S, non-discretionary) that reduces holdings modestly; it does not constitute a clear bearish signal on its own, and the data is complete for the single reported transaction. Cluster activity cannot be determined from this filing alone.
This transaction looks like routine sell-to-cover under a pre-established 10b5-1 plan rather than a discretionary bearish signal. For retail traders, itβs noise β not a tradeable event unless corroborated by multiple insiders or larger discretionary sales.